Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey R Oxnard

Showing results (71-80 of 199) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2025
Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical SamplesCloud P Paweletz, Alison Urvalek, Minh Ha, et al.
Cancer|April 17, 2015
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancerPeter C Lo, Suzanne E Dahlberg, Mizuki Nishino, et al.
Lung Cancer (Amsterdam, Netherlands)|December 30, 2023
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinomaLaura Burns, Hanna Tukachinsky, Kira Raskina, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertionsGeoffrey R Oxnard, Peter C Lo, Mizuki Nishino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2010
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutationGeoffrey R Oxnard, Maria E Arcila, Camelia S Sima, et al.
JAMA Oncology|April 8, 2016
Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung CancerAdrian G Sacher, Cloud Paweletz, Suzanne E Dahlberg, et al.
NPJ Precision Oncology|August 11, 2023
Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testingNadine Tung, Kali Chatham Dougherty, Emily Stern Gatof, et al.
Plos One|February 24, 2022
Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCRDrew F K Williamson, Sean R N Marris, Vanesa Rojas-Rudilla, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2013
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lungAndrew M Brunner, Daniel B Costa, Rebecca S Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2025
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational TrialsStacy S Shord, Cong Chen, Jin Y Jin, et al.
Pageof 20

Showing results (71-80 of 199) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2025
Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical SamplesCloud P Paweletz, Alison Urvalek, Minh Ha, et al.
Cancer|April 17, 2015
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancerPeter C Lo, Suzanne E Dahlberg, Mizuki Nishino, et al.
Lung Cancer (Amsterdam, Netherlands)|December 30, 2023
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinomaLaura Burns, Hanna Tukachinsky, Kira Raskina, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertionsGeoffrey R Oxnard, Peter C Lo, Mizuki Nishino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2010
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutationGeoffrey R Oxnard, Maria E Arcila, Camelia S Sima, et al.
JAMA Oncology|April 8, 2016
Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung CancerAdrian G Sacher, Cloud Paweletz, Suzanne E Dahlberg, et al.
NPJ Precision Oncology|August 11, 2023
Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testingNadine Tung, Kali Chatham Dougherty, Emily Stern Gatof, et al.
Plos One|February 24, 2022
Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCRDrew F K Williamson, Sean R N Marris, Vanesa Rojas-Rudilla, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2013
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lungAndrew M Brunner, Daniel B Costa, Rebecca S Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2025
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational TrialsStacy S Shord, Cong Chen, Jin Y Jin, et al.
Pageof 20